CIBC Asset Management Inc Increases Holdings in Insulet Corporation $PODD

CIBC Asset Management Inc boosted its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 70.3% during the fourth quarter, Holdings Channel reports. The firm owned 16,526 shares of the medical instruments supplier’s stock after acquiring an additional 6,821 shares during the quarter. CIBC Asset Management Inc’s holdings in Insulet were worth $4,697,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Larson Financial Group LLC grew its holdings in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares during the period. Elyxium Wealth LLC purchased a new position in shares of Insulet during the 4th quarter worth approximately $28,000. Fideuram Asset Management Ireland dac purchased a new position in shares of Insulet during the 4th quarter worth approximately $41,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Insulet during the 3rd quarter worth approximately $49,000. Finally, Osterweis Capital Management Inc. purchased a new position in shares of Insulet during the 2nd quarter worth approximately $51,000.

Insulet Stock Performance

Insulet stock opened at $153.22 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.49 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $10.61 billion, a P/E ratio of 35.63, a PEG ratio of 1.21 and a beta of 1.13. The stock’s 50 day moving average is $175.73 and its 200 day moving average is $238.90. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s quarterly revenue was up 33.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. On average, equities research analysts predict that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

PODD has been the topic of a number of research analyst reports. Barclays reduced their target price on Insulet from $286.00 to $198.00 and set an “underweight” rating on the stock in a report on Thursday, May 7th. BTIG Research reduced their target price on Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a report on Tuesday, May 26th. Canaccord Genuity Group reduced their target price on Insulet from $435.00 to $249.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Raymond James Financial reduced their target price on Insulet from $355.00 to $263.00 in a report on Thursday, May 7th. Finally, Rothschild & Co Redburn reiterated a “neutral” rating and set a $220.00 target price (down from $380.00) on shares of Insulet in a report on Friday, April 24th. Twenty-one research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $252.04.

Insider Buying and Selling at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the business’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were bought at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 0.36% of the stock is owned by insiders.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.